GBS - GBS gets approval to start validation trial for rapid sars-cov-2 diagnostic test

GBS ([[GBS]] +4.1%) have received approval from the Harvard Longwood campus Institutional Review Board ((IRB)) to commence a validation study to test clinical samples from a COVID-19 repository.The approval is the first step towards the validation of a rapid POC diagnostic that GBS intends to develop and commercialize for the quantitative measurement of antibodies against SARS-CoV-2.The repository’s samples will be sourced from clinical collaborators such as Brigham and Women’s Hospital, Massachusetts General Hospital, and Beth Israel Deaconess Hospital.GBS had announced a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to speed up the development of saliva-based diagnostic tests, in February.

For further details see:

GBS gets approval to start validation trial for rapid sars-cov-2 diagnostic test